Melbourne Clinical Trials
The Response Study
The study drug is a potential new treatment for Tuberous Sclerosis Complex.
24 nights
1 phone call visits
This study is an evaluation of a new potential treatment for certain brain disorders, including GRIN-related disorders, Tuberous Sclerosis Complex (TSC), and Focal Cortical Dysplasia (FCD)
This first phase is important before testing the treatment in people with these brain disorders. By joining, you will help research that could improve future treatments and make a positive impact on people and families dealing with these conditions.
Call us on 1300 533 682 to discuss your eligibility today!
Eligibility
Biological Sex Female or Male
Ethnicity Caucasian (defined as people who are of European, Middle Eastern, or North African descent)
Age 18-55 years old
BMI 18 - 32kg/m²
Weight more than 50kg
Medical History No significant medical history
Smoking History Non-smokers